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Pictorial abstract: Genes with 
SNPs identified significantly 
associated as risk for aggressive 
and non-aggressive Prostate 
Cancer. 
Environmental factors and risk of aggressive prostate cancer 
among a population of New Zealand men - a genotypic 
approach 
Venkatesh Vaidyanathana,b*, Vijay Naiduc, Chi Hsiu-Juei Kaoa,b, Nishi Karunasingheb, Karen S. Bishopb, Alice Wanga,b, Radha 
Pallatia, Phillip Shepherdd, Jonathan Masterse, Shuotun Zhua,b, Megan Goudiee, Mohanraj Krishnanf, Anower Jabedg, Gareth 
Marlowh, Ajit Narayananc, and Lynnette R. Fergusona,b 
Abstract: Prostate cancer is one of the most significant male health concerns worldwide. 
Numerous researchers carrying out molecular diagnostics have indicated that genetic 
interactions with biological and behavioral factors play an important role in the overall risk 
and prognosis of this disease. Single nucleotide polymorphisms (SNPs) are increasingly 
becoming strong biomarker candidates to identify susceptibility to prostate cancer. We 
carried out a gene x environment interaction analysis linked to aggressive and non- 
aggressive prostate cancer (PCa) with a number of SNPs. By this method, we identified the 
susceptible alleles in a New Zealand population, and examined the interaction with 
environmental factors. We have identified a number of SNPs that have risk associations 
both with and without environmental interaction. These indicate that, certain SNPs have 
been associated with disease vulnerability based on behavioral factors. The list of the genes 
with SNPs identified as risk of PCa in a New Zealand population is mentioned in the 
pictorial abstract.  
1. Introduction Prostate cancer (PCa) is one of the most 
significant male health concerns worldwide, due to 
its high prevalence and a risk of around 1 in 6 
patients developing the aggressive form of this 
disease1. Understanding of the risk of the disease 
becoming aggressive is important for the appropriate 
management of PCa2. PCa may start as an indolent 
disease of the prostate gland, followed by non-
castrate increase in prostate-specific antigen (PSA), 
followed by a non-castrate metastatic stage and 
finally progression to the lethal castration-resistant, 
aggressive disease3.  
In 2002, PCa was identified as the third-most 
prevalent cancer among adult males worldwide4 
and, after  a further ten years, PCa, as the second-
most common cancer among men and the sixth 
leading cause of death due to cancer among males 
worldwide5. The highest recorded rate of men with 
PCa, relative to the population of healthy men, is 
observed in the Oceania region6,7.  
Although a heredity aspect is known for PCa8, 
studies have also shown that genetic interactions 
a  Discipline of Nutrition and Dietetics, FM & HS, University of Auckland, 
Auckland 1023, New Zealand; v.vaidyanathan@auckland.ac.nz (V.V.); 
b.kao@auckland.ac.nz (C.H.-J.K.); alice.wang@auckland.ac.nz (A.W.); 
rpal628@aucklanduni.ac.nz (R.P.); st.zhu@auckland.ac.nz (S.Z.); 
l.ferguson@auckland.ac.nz (L.R.F.) 
b Auckland Cancer Society Research Centre, Auckland 1023, New Zealand; 
n.karunasinghe@auckland.ac.nz (N.K.); k.bishop@auckland.ac.nz (K.B.) 
c  School of Engineering, Computer and Mathematical Sciences, Auckland 
University of Technology, Auckland 1142, New Zealand; 
vijay.naidu@aut.ac.nz (V.N.); ajit.narayanan@aut.ac.nz (A.N.) 
d  Sequenom Facility, Liggins Institute, University of Auckland, Auckland 1023, 
New Zealand; p.shepherd@auckland.ac.nz (P.S.) 
e  Urology Department, Auckland District Health Board, Auckland, New Zealand; 
JonathanM@adhb.govt.nz (J.M.); MeganG@adhb.govt.nz  
f  Department of Obstetrics and Gynaecology, FMHS, University of Auckland, 
Auckland 1023, New Zealand; mohanraj.krishnan@auckland.ac.nz (M.K.) 
g  Department of Molecular Medicine and Pathology, FM & HS, University of 
Auckland,  
Auckland 1023, New Zealand; a.jabed@auckland.ac.nz (A.J.) 
h Experimental Cancer Medicine Centre, Cardiff University, Cardiff, CF14 4XN, 
United Kingdom; MarlowG@cardiff.ac.uk (G.M.) 
* Correspondence: v.vaidyanathan@auckland.ac.nz; Tel.: +64-9-923-6513; Fax: 
+64-9-373-7502 
ARTICLE Molecular Biosystems 
2 |Molecular Biosystems , 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
 
 
between biological and behavioral factors play an 
important role in the overall risk and prognosis of 
PCa9-11. Since decisions of clinical management are 
also based on identifying the risk of aggressive 
PCa3, extensive research is being carried out 
worldwide to identify the role played by  single 
nucleotide polymorphisms (SNPs), their association 
in the development and progression of PCa and their 
potential use as biomarkers12,13. SNPs are 
increasingly becoming strong biomarker candidates 
to identify PCa susceptibility12,14,15. Due to the 
increasing number of cases of PCa, identifying one 
or more biomarkers for early detection and proper 
management of PCa to avoid disease progression 
into the aggressive state is becoming an urgent 
priority internationally16.  
It is recognized that one form of defense against 
cancer development involves a series of genes 
whose role is to metabolize and excrete potentially 
toxic compounds and to repair subtle mistakes in 
DNA such as the mismatch repair genes. Particular 
environmental exposures can exacerbate the genetic 
influence on PCa through gene x environment 
interaction17.  
This paper explores the use of SNP genotypes as 
biomarkers for aggressive PCa. Here we present the 
data obtained following the genotype analysis of 138 
SNPs, located in 60 genes and 10 chromosomal 
locations using SEQUENOM MassArray 
technology and the TaqMan SNP genotyping 
procedure. The cohort includes New Zealand men 
(of European descent) with different grades/stages 
of PCa, and age matched male controls. We seek to 
detect the association of SNPs with both aggressive 
and non-aggressive disease as well as the influence 
of external factors in risk modification. This, we 
believe, is the first such study on genetic and 
environmental risk association and interaction 
analysis leading to aggressive PCa in a New Zealand 
cohort.  
2. Materials and Methods  
2.1 Study population: 
Patients with proven diagnosis for prostate 
cancer from the Auckland Regional Urology 
Registry (Auckland, Middlemore, and North Shore 
hospitals), and private practices in the Waikato 
region, New Zealand were invited to take part in this 
study between 2006- 2014 (ethics reference 
NTY05/06/037). Patient recruitment was carried out 
with their informed consent. Initially, patients were 
recruited within one year of diagnosis, if they have 
not undergone any treatment for PCa. In 2008, the 
criterion was relaxed to include all patients with 
malignancies, regardless of treatment but within 1 
year of diagnosis. In September 2010, the time frame 
for recruitment was removed altogether. From those 
that took part in this study, a total of 197 men were 
identified with aggressive PCa, and 57 with non-
aggressive PCa. Additionally, 369 healthy males 
took part in our studies (ethics reference 
NTY/06/07/AM04), who were considered as 
healthy controls. The age of patients varied from 40- 
81 years at the time of recruitment and those with a 
self-reported European ancestry were included in the 
study. 
2.2 Data collection for demography, and lifestyle 
details: 
Each patient completed a demographic and 
lifestyle questionnaire at entry into the study. The 
questionnaire included details about the individual’s 
history of smoking tobacco, consumption of alcohol, 
body mass index (BMI) at time of recruitment, and 
age at diagnosis of PCa. Current smokers and 
individuals who reported a history of smoking 
tobacco were jointly considered as smokers.  
The clinical history of each patient was 
extracted from hospital databases and transferred to 
a central study database. The age at which PCa was 
diagnosed in patients and the age at recruitment for 
the controls were considered as age for analysis.  
2.3 Collection and processing of blood samples: 
Blood samples from each volunteer were 
collected in Vacutainer® tubes (Becton Dickinson) 
containing Ethylene Diamine Tetra Acetic acid 
(EDTA). An aliquot of the sample collected was 
then used for genomic DNA extraction. Each 
patient’s DNA was extracted using a QIAamp 
genomic DNA kit (Qiagen, Hilden, Germany) 
following the manufacturers’ protocol with the aid 
of a fully automated QIAcube (Qiagen, Hilden, 
Germany). The DNA samples were diluted to  
5.0ng/μl as per requirement of the SEQUENOM 
MassARRAY iPLEX® assay protocol.  
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00 , 1-3 | 3  
 
 
2.4 Selection of SNPs: 
A total of 135 SNPs, located in 66 genes and 
some undefined chromosomal locations 
(Supplementary Table 1) were identified by a 
literature search of the published genome-wide 
association studies (GWAS) for both PCa and its 
aggressive form.  
The PubMed database was screened for 
research articles using key terms “prostate cancer” 
and/or “aggressive prostate cancer”, along with 
“SNP genotyping sequenom massarray iplex”, 
and/or “genome-wide association studies”. Only 
research articles published on or after the year 2000 
were considered for this study to maintain the 
current trend of research. Since the sample 
population for this research is of European ancestry, 
attention was given to research papers which 
reported statistically significant findings among 
patients with such backgrounds.  
The research team has also used their own 
knowledge and discretion regarding which SNPs to 
be genotyped using SEQUENOM MassARRAY 
iPLEX® assay, or the TaqMan SNP genotyping 
assay. Various metabolic pathways such as selenium 
metabolism and androgen metabolism pathway were 
included, for instance, as was, screening for 
chromosomal regions such as 8q24, 10q11, 17q12, 
and Xp11 all known for PCa risk association. 
Additionally certain putative oncogenes such as 
MYEOV (Myeloma Overexpressed), and DNA 
mismatch repair genes such as MLH1 (MutL 
homolog 1); as well as certain genes with an 
established role in the PSA metabolism 
pathway7,10,18 were also considered in this 
assessment.  
 
Our approach uses genome wide association 
analysis (GWAA)  to provide a comprehensive 
evaluation of multiple genes with polymorphisms 
that interact in the same pathway/s, in line with 
proposals made by Hsing et al., (2008)19 and Kwon 
et al., (2012)20, who claim that studies on GWAA 
are a better way to study multifactorial diseases such 
as PCa. Also, Hsing et al., (2008), have suggested 
that research pertaining to the AR pathway should 
include co-regulators along with important genes 
involved in androgen metabolism and 
biosynthesis19. A similar approach was followed in 
our selection of genes with the SNPs studied below. 
2.5 SNP genotyping of candidate genes: 
2.5.1 SNP genotyping by Sequenom multiplexing: 
Genotyping for the candidate SNPs was carried 
out in the Auckland UniServices Sequenom Facility 
at Liggins Institute, Auckland, and AgResearch 
Limited, Mosgiel, New Zealand, using  custom-
designed multiplex gene panel and iPlex chemistry. 
Genotype calling was performed using the standard 
post-processing calling parameters in SEQUENOM 
Type 4.0 software. Each 384-well plate prepared for 
genotyping contained known HAPMAP control 
samples, negative controls (Water) and repeats of 
samples used in different locations in the 384-well 
plate for validation of the genotyping procedure. 
2.5.2 SNP genotyping by TaqMan® assay: 
SNP genotyping using TaqMan® SNP 
genotyping (Applied Biosystems) was carried out on 
a panel of genes. The primers used were either 
obtained pre-designed from Applied Biosystems or 
were custom-made using Assay-by-Design service 
by ABI7,10,18. The protocol provided by the 
manufacturers (Applied Biosystems) was used to 
carry out the SNP genotyping7,10,18.  
 
 
2.6 Collection of clinical characteristics of 
patients: 
The total serum PSA level and Gleason score of 
the tumour at biopsy or post-surgery or both were 
obtained from the patients’ clinical records at the 
time of recruitment or subsequent to recruitment. 
Post-surgery Gleason score was given priority over 
biopsy Gleason score. Staging data was collected 
from clinical records during the years 2013- 2014, 
but was not available for all the patients.  
2.7 Definition of aggressiveness: 
The aggressiveness of PCa for this study is 
based on the classification used by the American 
Urological Association21 and first proposed by 
D’Amico et al. (1998) for defining high-risk or 
aggressive PCa as clinical T stage ≥T2c, or Gleason 
score ≥8, or serum PSA level >20ng/ml22.  
2.8 Statistical analysis: 
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2.8.1 SNP data cleaning: 
A total of 39 SNPs were removed from the list 
before data analysis after checking the genotype for 
compliance with Hardy Weinberg Equilibrium 
(HWE) and in order to avoid linkage disequilibrium 
using PLINK23. 13 SNPs were reduced for not 
complying with HWE and an additional 26 SNPs 
were removed for being in linkage. The entire list of 
the SNPs removed from the final analyses is colour-
coded in the Supplementary table 1. We therefore 
analysed the data using a reduced list of 99 SNPs. 
Analysis of the data for SNP association with 
PCa based on aggressiveness and gene x 
environment interaction for risk of PCa were both 
carried out using PLINK- a tool set for whole 
genome association23. Correction for multiple 
testing was applied to significance value where 
appropriate otherwise, statistical significance was 
set at p≤0.05 24.  
2.8.2 SNP association analysis for risk of Prostate 
Cancer: 
A structured association approach similar to the 
one proposed by Arya et al., in 200925, working on 
rheumatoid arthritis, was followed. This provides a 
simple but powerful method, to detect population 
stratification, and is implemented in the 
PLINK23,25,26.  
PLINK's clustering approach is based on the 
genome-wide average proportion of alleles shared 
identical-by-state (IBS) between two individuals 
SNPs, i.e., pairing up the SNPs based on genetic 
identity23. The IBS clustering is used to test whether 
the SNPs of two individuals belong to the same 
population. Following the stratification analysis, we 
performed a standard case-control association test 
using a Cochran-Mantel-Haenszel statistic (1 df 
(degree of freedom)) that tests for SNP-disease 
association conditional on the clustering. This 
accounts for stratification effects, as has been 
reported by Arya et al. (2009)25. 
To avoid the possibility of false positives with 
multiple SNP testing, statistical significance was 
restricted by the most conservative Bonferroni 
correction (BONF) along with the less conservative 
Benjamini and Hochberg false discovery rate (BH-
FDR) for multiple testing corrections. The complete 
set of results is provided in Supplementary Table 2. 
However, as the tested SNPs were already shown 
statistically to be significantly associated with PCa 
risk by other researchers11,27,28, variations that 
demonstrated significant association to risk of PCa 
before BONF and BH-FDR were considered for 
discussion in our study.  
2.8.2 Significance of demographic factors: 
The variation of lifestyle characteristics 
between pathology was tested using the Fisher exact 
test.  
The BMI data were not normally distributed; 
therefore comparisons between pathologies were 
carried out using the Mann Whitney test. 
2.8.3 Gene-environment interaction for risk of PCa: 
The covariates included the three environmental 
factors of- BMI record, tobacco smoking and 
alcohol consumption history. Also three genotypic 
models: additive (ADD), dominant deviation 
(DOMDEV), and general_2 df joint test of both 
additive and dominant deviation (GENO_2DF) were 
generated. An additive model represents the additive 
effects of SNPs i.e., the effect of each additional 
minor allele as represented by the direction of the 
regression coefficient. For example, a positive 
regression coefficient indicates that the minor allele 
increases risk. A DOMDEV model represents a 
separate test of the dominance component, and a 
general model represents the joint test of both ADD 
and DOMDEV components. However, in contrast to 
a dominance model, ADD refers to a variable coded 
in such a way (0, 1, 0 for three genotypes AA, Aa, 
aa) that it represents the dominance deviation from 
additivity without specifying whether a particular 
allele is dominant or recessive. Effects of genotype 
× environmental (BMI, tobacco smoking and 
alcohol consumption) interactions was tested and 
eventually corrected for. 
 
3. Results 
3.1 Gene x -environment effects and prostate 
cancer risk in a New Zealand population: 
The tables show the results of the statistically 
significant SNPs associated between non-aggressive 
PCa and healthy controls (Table 1.1), between 
patients with aggressive and non-aggressive PCa 
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(Table 1.2), and patients with aggressive PCa and 
healthy controls (Table 1.3), all assessed before the 
use of BONF. . 
The results obtained after a detailed analysis of 
the association of SNPs as risk of PCa can be 
broadly classified into two categories- expected, and 
unique with respect to the results reported by other 
groups.  
Certain SNPs present near genes such as 
MYEOV- a putative oncogene (Table 1.3); TLR4 
(Toll-like receptor 4) (Tables 1.1 and 1.2) and 
MMP9 (Matrix metallopeptidase 9) (Table 1.2)- 
involved with the inflammatory pathway; and KLK3 
(Kallikrein-3) (Table 1.2 and 1.3) and MSMB 
(Microseminoprotein Beta ) (Table 1.3)- both 
involved in the PSA metabolism pathway were 
understandably identified as statistically significant 
in our study, due to their proven risk association to 
PCa.  
The number of SNPs present near various genes 
associated with obesity and diabetes mellitus such as 
FADS2 (Fatty acid desaturase 2) (table 1.3), LEP 
(Leptin) (Tables 1.2 and 1.3), PPAR-Ȗ (Peroxisome 
Proliferator-Activated Receptor gamma) (Table 1.3) 
were associated with the risk of aggressive PCa vs 
healthy controls as recorded in our analysis. 
 
Table 1.1: Statistically significant Case/Control SNP association between patients with non-aggressive prostate cancer and 
healthy controls  
Sl. No. SNP ID Gene name 
Gene 
location 
Tested 
allele 
Odds Ratio p-Value 
1 rs2292884     MLPH 2q37.2 G 1.774 0.02375 
2 rs4965373     SEPS1 15q26.3 A 1.801 0.02413 
3 rs11536889     TLR4 9q33.1 C 2.198 0.02727 
4 rs3735035     PODXL 7q32 C 1.572 0.03493 
Table 1.2: Statistically significant Case/Control SNP association between patients with aggressive prostate cancer and non-
aggressive prostate cancer  
Sl. No. SNP ID Gene name 
Gene 
location 
Tested 
allele 
Odds 
Ratio 
p-Value 
1 rs632148     SRD5A2 2p23.1 C 1.799 0.01731 
2 rs887391     SLC26A6 19q13 C 1.793 0.02063 
3 rs11536889     TLR4 9q33.1 G 2.303 0.02251 
4 rs2292884     MLPH 2q37.2 A 1.801 0.02614 
5 rs3735035     PODXL 7q32 T 1.621 0.03126 
6 rs10244329     LEP 7q33 T 2.062 0.03222 
7 rs17632542     KLK3 19q13.33 T 3.194 0.04647 
8 rs3918256     MMP9 20q13.12 A 1.555 0.04959 
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Table 1.3: Statistically significant Case/Control SNP association between patients with aggressive prostate cancer and 
healthy controls  
Sl. No. SNP ID Gene name 
Gene 
location 
Tested 
allele 
Odds 
Ratio 
p-Value 
1 rs17793693    PPAR-γ 3p25 A 4.534 0.000173 
2 rs7931342    MYEOV 11q13 T 1.565 0.0007423 
3 rs10896438    MYEOV 11q13.3 T 1.4985 0.002322 
4 rs887391    SLC26A6 19q13 C 1.594 0.005094 
5 rs5945619    NUDT11  Xp11 T 1.694 0.005749 
6 rs17632542    KLK3 19q13.33 T 1.998 0.008268 
7 rs7920517     MSMB 10q11 A 1.400 0.01227 
8 rs11228565      MYEOV 11q13 G 1.433 0.02189 
9 rs10244329     LEP 7q33 T 1.557 0.02344 
10 rs6983561       8q24 A 1.885 0.02883 
11 rs130067     CCHCR1 6p21.3 A 1.383 0.03656 
12 rs2727270     FADS2 11q13 C 1.525 0.04184 
13 rs12529     AKR1C3 10p15 C 1.294 0.04685 
14 rs2659122     KLK3 19q13.33 A 1.345 0.04748 
Tables 1.1- 1.3 colour legends risk association: 
  Common SNPs between (Agg PCa vs Healthy Control) and (Agg PCa vs Non-Agg PCa) 
  Common SNPs between (Non-Agg PCa vs Healthy Control) and (Agg PCa vs Non-Agg PCa) 
3.2 Pathology, BMI and lifestyle: 
Owing to the established role of environmental 
or non-genetic aspects in the expression of genes29 
in PCa30, we compared the variation in 
demographics and lifestyle factors such as age, 
alcohol consumption, smoking tobacco, and levels 
of obesity among the patients recruited for our study. 
The disease association with BMI (based on the 
classification by World Health Organization31) at the 
time of recruitment, tobacco smoking  status, and 
alcohol consumption (at the time of recruitment in 
this study) are provided in tables 2.1 to 2.3 
respectively.  In these tables the controls are 
compared to  non-aggressive and  aggressive PCa 
patients.  
Table 2.1: The association between BMI and risk and/or aggressiveness of prostate cancer  
Compared 
groups 
Pathology 
N’ Median 
(75th percentile) 
Mann-
Whitney U 
test 
p-value 
(N & UW) (OW & O) Total 
Aggressive 36 161 197 27.00 (30.50) 
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Aggressive vs 
Control  
Control 122 247 369 26.36 (29.12) 31166.00 0.005 
Aggressive vs 
Non-Aggressive 
Aggressive 36 161 197 27.00 (30.50) 
5450.50 0.737 
Non-Aggressive 8 49 57 27.00 (29.00) 
Non-Aggressive 
vs Control 
Non-Aggressive 8 49 57 27.00 (29.00) 
9115.00 0.105 
Control 122 247 369 26.36 (29.12) 
Table legends: N= men with normal weight (18.50 kg/m2- 24.99kg/m2); UW= men who were under-weight (<18.50 
kg/m2); OW= men who were over-weight (25.00 kg/m2- 29.99 kg/m2); O= men who were obese (≥30.00 kg/m2); N’= 
number of men 
Table 2.2: Association between tobacco smoking status and risk and/or aggressiveness of prostate cancer 
Compared groups Pathology 
N’ Percentage 
(ever smokers) 
OR 
(95% CI) 
p-value 
No Yes Total 
Aggressive vs 
Control  
Aggressive 89 108 197 54.82% 1.893  
(1.31- 2.73) 
0.0003766 
Control 225 144 369 39.02% 
Aggressive vs Non-
Aggressive 
Aggressive 89 108 197 54.82% 0.821 
(0.42- 1.55) 
0.5477 
Non-Aggressive 23 34 57 59.64% 
Non-Aggressive vs 
Control 
Non-Aggressive 23 34 57 59.64% 2.3098 
(1.30- 4.08) 
0.003871 
Control 225 144 369 39.02% 
Table legends: N’= number; 95% CI= 95% confidence interval, No= never smokers, Yes= ever smoker 
Table 2.3: Comparison of alcohol consumption and risk and/or aggressiveness of prostate cancer 
Compared 
groups 
Pathology 
N’ Percentage 
(alcohol 
consumers) 
OR (95% CI) p-value 
No (1) Yes (0) Total 
Aggressive vs 
Control  
Aggressive 79 118 197 59.89% 0.256  
(0.16- 0.39) 
2.73e-11 
Control 54 315 369 85.36% 
Aggressive vs 
Non-Aggressive 
Aggressive 79 118 197 59.89% 1.166 
(0.61- 2.20) 
0.6479 
Non-Aggressive 25 32 57 56.14% 
Non-Aggressive 
vs Control 
Non-Aggressive 25 32 57 56.14% 0.220 
(0.121- 0.399) 
1.456e-06 
Control 54 315 369 85.36% 
Table legends: N’= number; 95% CI= 95% confidence interval 
3.3 Correction for the effect of covariants to 
identify the genic risk of  aggressive PCa: 
The statistically significant results obtained 
using logistic models after adjustments for multiple 
covariatesare presented in tables 3.1 and 3.2 
(Aggressive PCa vs non-aggressive PCa and 
aggressive PCa vs healthy control are shown in 
tables 3.1 and 3.2 respectively). The data obtained 
for non-aggressive PCa vs healthy control was not 
statistically significant and will not be further 
addressed in this paper. 
The results obtained after the interaction 
analysis can also be broadly classified into two 
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categories- expected, and unique to the New Zealand 
population studied. The New Zealand aspect of gene 
x environment interaction was much better evident 
after analyzing these results.  
Certain SNPs present near genes such as 
MYEOV- a putative oncogene (Table 3.2); KLK3 
and MSMB (both, Table 3.2)– involved in the PSA 
metabolism pathway; MMP9 (Table 3.1)- involved 
with the inflammatory pathway; and MLH1 (Table 
3.2), which has a role in DNA mismatch repair were 
identified as statistically significant in our study as 
expected. However, we had some novel findings as 
well.  
A SNP present near the gene LEP (Tables 3.1 
and 3.2), associated with obesity is identified as 
statistically significant risk for both aggressive and 
non-aggressive PCa; and the SNP present near the 
gene SEP15 (Seleoproten 15kDa)- involved with 
quality control of protein folding in the endoplasmic 
reticulum (ER) may reveal new knowledge about the 
changes of risk for aggressive PCa with local 
environmental conditions and its effects on the New 
Zealand Caucasian men studied here. 
 
Table 3.1: Logistic model of SNPs risk for aggressive prostate cancer vs non-aggressive prostate cancer after correcting for 
interaction with multiple covariates (BMI, tobacco smoking, and alcohol consumption)  
Sl. No. SNP ID Gene name 
Gene 
location 
Tested allele Odds Ratio p-value 
1 rs632148 SRD5A2 2p23.1 C 2.144 0.01196 
2 rs10244329     LEP 7q33 T 2.395 0.02893 
3 rs3918256     MMP9 20q13.12 A 1.873 0.03109 
4 rs3735035     PODXL 7q32 T 1.625 0.03561 
Table 3.2: Logistic model of SNPs risk for aggressive prostate cancer vs healthy controls after correcting for interaction with 
multiple covariates (BMI, tobacco smoking, and alcohol consumption)  
Sl. No. SNP ID Gene name 
Gene 
location 
Tested 
allele 
Odds Ratio p-value 
2 rs10896438 MYEOV 11q13 T 1.699 0.000421 
1 rs7931342 MYEOV 11q13 T 1.705 0.000423 
3 rs7920517 MSMB  10q11 A 1.590 0.001734 
6 rs5845 SEP15 1p22.3 C 1.845 0.01333 
5 rs2659122 KLK3 19q33.33 A 1.702 0.01516 
4 rs1799977 MLH1 3p21 G 1.53 0.0202 
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7 rs10244329     LEP 7q33 T 1.639 0.03245 
8 rs12529     AKR1C3 10p15 C 1.318 0.04006 
9 rs887391     SLC26A6 19q13 C 1.639 0.04449 
Tables 3.1-3.2 colour legend showing risk association: 
  Common SNPs between (Agg PCa vs Healthy Control) and  (Agg PCa vs Non-Agg PCa) classification 
 
4. Discussion 
It is well established that there are three major 
risk factors for PCa, namely, advancing age32, 
ethnicity, and familial history33. Various studies 
have indicated that alterations in genetic and 
epigenetic make-up are predominantly the basis for 
the development of various malignancies15,34,35. In 
this study, SNP genotype data was used to identify 
risk association with aggressive PCa while the effect 
of non-genetic or environmental factors was also 
considered.  
4.1 Effect of environment and SNP genotype with 
risk of prostate cancer: 
Parts of the panel of SNPs used in this analysis 
have previously been considered to assess PCa risk 
(Supplementary table 1). However, the approach 
here is to assess their significance to aggressive PCa 
also. Out of the 99 SNPs studied,  4 SNPs were 
significantly associated with non-aggressive PCa 
when compared with healthy controls, and 8 SNPs 
were identified to be significantly associated with 
aggressive PCa compared to non-aggressive PCa. 
Also, 14 SNPs were identified to be significantly 
associated with aggressive PCa when compared with 
healthy controls (Tables 1.1-1.3 respectively). The 
majority of the SNP associations lost significance 
after correcting for multiple testing using the BONF, 
an overly conservative approach, and the BH-FDR, 
a less conservative correction that tolerates more 
false positives. 
Large scale GWAS have previously shown 
direct SNP associations with aggressive PCa. 
However, SNP interactions with demographic and 
lifestyle factors could also add to the allelic effect 
producing a modified risk of a disease. These SNPs 
could be indicating a unique situation for New 
Zealand men- who are an example of isolated men 
of European origin, with PCa.  Of particular interest 
in the New Zealand context are, aspects such as 
obesity36, higher intake of red meat and dairy 
products, and possible deficiency in selenium intake. 
All of these could impact on genetic mechanisms in 
ways that may lead to a higher risk of aggressive 
PCa.  
The three broad classifications under which the 
data were analyzed are SNP associations between 
patients with aggressive PCa and healthy controls, 
between patients with non-aggressive PCa and 
healthy controls and between patients with 
aggressive and non-aggressive PCa. The results for 
these groups are discussed below.  
 
4.1.1 SNP genotype analysis of non-aggressive 
prostate cancer vs healthy controls: 
Of the 4 SNPs identified as significant risk for 
non-aggressive PCa vs healthy controls, 3 SNPs 
were identified to be commonly associated to risk of 
the progression of this disease (aggressive PCa vs 
non-aggressive PCa). These SNPs include 
rs2292884 in chromosomal region 2q37 near the 
gene MLPH (Melanophilin), rs3735035 present in 
chromosomal region 7q32 in the gene PODXL 
(Podocalyxin-like), rs10086908 present in 
chromosomal region 8q24 and rs11536889 present 
in chromosomal region 9q33 near the gene TLR4.  
The TLR4 gene is responsible for activating 
innate immunity in humans37,38. TRL4 is one of 13 
transmembrane receptors found in the troll-like 
receptors family which plays an important role in 
chronic infection and inflammation pathways, in 
turn controlling the incidence of development of 
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cancer38,39. The expression of the TLR4 protein in 
PCa is already well established38.  
SNP rs2292884 close to chromosomal region 
2q37 near the gene MLPH, was also identified to be 
statistically significantly associated with non-
aggressive PCa compared to controls. Very little is 
known about the possible functional impact of 
MLPH in carcinogenesis and/or tumor progression 
40
. Dysregulation of the protein MLPH has recently 
been found in several types of tumors in lung cancer, 
meningiomas, and of breast cancers41-43. A recent 
study found an association of expression of the gene 
MLPH with nearby SNPs in prostate tissue44. In non-
small cell lung cancer, MLPH mRNA was identified 
as a target of differentially expressed miRNAs45. 
Interestingly, the protein MLPH was also found to 
be significantly overexpressed in estrogen receptor 
(ER) positive breast cancer, suggesting a regulation 
of this protein by estrogen hormones43. 
SNP rs3735035 present in chromosomal region 
7q32 in the gene PODXL was also identified to be 
significantly associated with non-aggressive PCa 
(before the use of BONF) in our study. PODXL is a 
cell-adhesion glycoprotein and stem cell marker that 
has been associated with an aggressive tumour 
phenotype and poor prognosis in several forms of 
cancer46,47. Interestingly, the first report of PODXL 
expression in malignant cells was its description as 
a stem cell marker in testicular cancer48 and it has 
been previously identified as a candidate biomarker 
for PCa aggressiveness49. Since rs3735035 present 
in this gene came up as statistically significantly 
associated with non-aggressive PCa (before the use 
of BONF) in our population, we feel that this SNP 
may play a role from the point of disease initiation.  
SNP rs4965373 present in chromosomal region 
15q26.3 in the gene SEPS1 (selenoprotein S) was 
also identified to be statistically significantly 
associated with non-aggressive PCa (before the use 
of BONF) in our population. The human gene 
SEPS1, encodes selenoprotein S which participates 
in the retro-translocation of misfolded proteins from 
the ER to the cytosol for their degradation50. This ER 
membrane protein functions in stress responses to 
prevent the deleterious consequences of 
accumulation of misfolded proteins, that has been 
linked to immune and inflammatory processes51. 
The SEPS1 gene was first suggested to be related to 
the stress response process including immune and 
inflammatory processes through the study of Curran 
et al., in 200552. In addition, several diseases, 
including inflammatory disorders53 such as insulin-
dependent diabetes mellitus54, and gerontological 
disorders such as Alzheimer’s disease55, have been 
shown to be linked to this gene region. The A allele 
of this rs4965373 SNP has previously shown 
positive associations with serum Selenium levels in 
a healthy male population from New Zealand56. 
Comparing the current findings with those of 
Ferguson et al. (2012) indicates a possibility for 
retention of excess selenium as a cause of non-
aggressive PCa risk. These direct us to the relation 
between functional defects, inflammation, 
immunity, and its depletion due to ageing as 
responsible for initiation of diseases such as PCa.  
4.1.2 SNP genotype analysis of aggressive prostate 
cancer vs non-aggressive prostate cancer: 
Non-aggressive PCa can be considered as an 
intermediary between healthy and aggressive PCa 
states. We identified a number of SNPs to be 
common between the categories of SNP association 
between aggressive PCa and healthy controls and 
non-aggressive PCa and healthy controls.  
Among these common SNPs are those in genes 
that have been identified to play roles in immunity 
(rs1153688957), development and progression of 
PCa (rs229288440, and rs373503558).   
The SNPs common to be associated with 
aggressive PCa compared to controls and the SNPs 
identified to be associated with the progression of 
this disease (aggressive PCa vs non-aggressive PCa) 
are rs10244329 in 7q33.3 chromosomal region near 
the gene LEP, rs887391 and rs17632542, both 
present in chromosomal region 19q13. Of the SNPs 
that are common to be associated to non-aggressive 
PCa compared to controls and the SNPs identified to 
be associated with the progression of this disease 
(aggressive PCa vs non-aggressive PCa), there are 
SNPs in genes that have been identified to play roles 
in the expression of PSA (rs1763254259,60), 
development and progression of PCa (rs88739161), 
and morbid obesity62,63.  
SNPs rs632148 in the gene SRD5A2 (Steroid 
5α-reductase type 2) on chromosomal region 2p23, 
and rs3918256 in the gene MMP9  have also been 
associated with aggressive PCa when compared to 
non-aggressive PCa patients. The SNPs rs632148  
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and rs3918256 have been previously reported by 
groups working on various aspects related to and 
causing PCa in Caucasian populations and not 
restricted to studies pertaining to quality of sperms 
(rs632148)64, and also contribute to the invasive and 
metastatic properties of malignant tumors, including 
those of the prostate (rs3918256)65. These SNPs are 
of considerable importance in understanding the 
overall progression of PCa to aggressive stage.  
4.1.3 SNP genotype analysis of aggressive prostate 
cancer vs healthy controls: 
A link between SNPs in the 11q13 region and 
PCa has been previously identified by various 
GWAS66-69.  Three SNPs-  rs10896438, rs7931342, 
rs11228565, present in MYEOV and one SNP-  
rs2727270 present in FADS2  are identified to be 
statistically significant before the use of BONF 
when comparing the controls to those with 
aggressive PCa. Frequent rearrangements are 
observed in human cancers in the area 11q1370.  Four 
out of fourteen SNPs identified to have a statistically 
significant risk association with aggressive PCa,  
were identified in one location. This region houses a 
number of candidate oncogenes, and the 
amplification of this region is highly heterogeneous 
leading to breakpoints in and/or near the 
location71,72. MYEOV has been shown to be 
frequently amplified in tumours not only of the 
breast but also of the oesophagus73 and head and 
neck squamous cell carcinoma71.  
Of the 3 SNPs present in 19q13 region, 2 
(rs2659122 and rs17632542) are located in the gene 
region KLK3, which codes for PSA- a glycoprotein 
enzyme, secreted by epithelial cells of the prostate 
gland. Men with serum PSA levels of more than 
20ng/ml are categorized as having aggressive PCa74. 
Therefore, it is not surprising that a number of SNPs 
in the gene KLK3 were identified as statistically 
significant when comparing men with aggressive 
PCa and controls. This is similar to the findings 
discussed in other GWAS for aggressive PCa66. The 
third SNP in this region, rs887391, present in gene 
SLC26A6 (Solute carrier family 26 member 6)- a 
fusion gene which is crucial for the development and 
the progression of various human cancers75, is about 
10Mb centromeric to the KLK3 gene, where the SNP 
rs2735839, near 3’ end is found66,76.  
The chromosomal region, 8q24 has been of 
considerable interest in terms of development and 
epidemiology of cancer77. Ahmadiyeh et al., (2010) 
suggested that numerous, non-dependent 
polymorphic variants present in the chromosome 
location 8q24 may produce certain biological 
mechanisms that contribute to disease, or, 
alternatively, the 8q24 regions may cumulatively 
influence the regulation of adjacent genes (cis-
regulation) or genes on other chromosomes (trans-
regulation)78. The SNP rs6983561 identified to be 
significantly associated with aggressive PCa 
compared to controls among our population before 
the use of BONF, however, is commonly found in 
the Asian population, rather than the Caucasian 
population79.  
10q1180,81 and Xp1180-82 are two other 
chromosomal regions that are identified to have a 
number of SNPs associated with PCa in Caucasian 
populations. We identified one SNP, in each of the 
two aforementioned locations to be significantly 
associated with aggressive PCa compared to 
controls before the use of BONF. These are 
rs7920517 present near the gene MSMB, and 
rs5945619 present in the gene NUDT11 (Nucleoside 
Diphosphate-linked Moiety X Motif 11) 
respectively. These SNPs knit a very tight story and 
are of considerable interest.  
MSMB is one of just three predominant 
proteins, along with PSA and prostatic acid 
phosphatase secreted by a normal human prostate 
gland83. The PSA level in men is usually measured 
to estimate the health of a prostate gland, and 
MSMB, owing to its varied expression levels in 
cancer cells compared to the prostate epithelial cells 
in the benign stage, is implicated as a potential PCa 
biomarker84,85. MSMB is also known to modulate 
immunoglobulin levels in hypoxic tumour cores86.  
The SNP rs594561969,87 present in the Xp11 
region also has been identified to be significantly 
(before BONF were implemented) associated with 
aggressive PCa to controls. This SNP is present near 
the paralogous human gene NUDT11, 
predominantly expressed in the testes, and may play 
a role in signal transduction88,89. A number of 
GWAS have also suggested that the susceptibility 
locus at NUDT11 may have involvement with risk 
of PCa66,81,87,90,91.        
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The SNP rs17793693 present in the PPAR-Ȗ 
gene was also identified to be significantly 
associated with aggressive PCa in our population. 
The significance, however, was lost after the BONF 
was implemented. PPAR-Ȗ ligands induce growth 
arrest in cells through apoptosis, in both 
macrophages92 and endothelial cells93. Among other 
roles, the PPAR-γ protein has also been identified to 
be having a role in immunity94,95. The PPAR-Ȗ gene, 
present in the 3p25 region of the human genome has 
been suggested to have an association with PCa by 
various researchers28,95. PPARs (comprising of 
PPAR-α, PPAR-ȕ and PPAR-γ genes) are members 
of the nuclear hormone receptor superfamily of 
ligand-activated transcription factors including 
receptors for steroid hormones, Vitamin D3, retinoid 
and thyroid hormones95,96. The PPAR-γ gene has 
been identified to be mainly present in adipose 
tissues, wherein it plays a vital role in the pre-
adipocytes to adipocytes95. The PPAR-γ gene has 
also been identified to be involved in the pathology 
and progression of various diseases including 
obesity and diabetes mellitus97. Diabetes mellitus 
has previously been associated with PCa, such that 
patients with diabetes have been suggested to be at a 
lower risk of PCa98. Certain metabolic factors 
including reduced testosterone levels may affect 
blood glucose level98,99.  
SNPs rs130067 present in 6p21.3 chromosomal 
region near the gene CCHCR1 (coiled-coil alpha-
helical rod protein1), rs10244329 present in 7q33.3 
chromosomal region near the gene LEP and rs12529 
present in chromosomal region 10p15 in the gene 
AKR1C3 (Aldo-keto reductase family 1 member C3) 
have also been identified to be statistically 
significantly associated with aggressive PCa in this 
study. The AKR1C3 rs12529 G allele has been 
previously associated with PCa risk when 
interacting with age and lifestyle habits including 
tobacco smoking11. It could be that although the G 
allele of this SNP is producing a risk for PCa, it is 
the C allele that produces aggressiveness of the 
disease. A study by Yu et al., (2013)100 has shown 
that this C allele is responsible for prostate cancer- 
specific mortality among those receiving androgen 
deprivation therapy . The same allele has also shown 
retention of cancer-specific symptoms, if managed 
only with non-androgen deprivation treatment 
methods101. The SNPs rs130067, rs10244329, and 
rs12529 have been previously reported by groups 
working on various diseases related to and causing 
PCa in Caucasian populations such as rheumatoid 
arthritis13, obesity102, and sex hormone metabolic 
pathway11,103,104 respectively. The rs12529 SNP is 
also related to lung cancer105 and bladder cancer106.  
4.2 Age and risk of prostate cancer: 
Age is a major risk factor for PCa32,107. 
However, in the data presented in our present study 
we did not consider the role of ageing, as it is the 
only external factor which cannot be reversed, but 
the other aspects such as high (or, low) BMI, 
smoking tobacco and alcohol consumption habits 
can be altered by individuals. Moreover, we wanted 
to see the effect of gene x environment aspects 
prevalent in our local population in the expression 
and progression of PCa.  
4.3 BMI, smoking tobacco, and alcohol consumption 
at recruitment and risk of prostate cancer: 
Our previous research showed that BMI is not 
statistically different in age matched controls and 
those with benign urology disease7. However, with 
the current stratification BMI was shown to be 
significantly higher (27.00kg/m2) among those with 
aggressive PCa compared to controls (26.36kg/m2). 
The mean BMI at recruitment of all our groups 
(cases as well as healthy controls) was calculated to 
be in the category of overweight for adults. 
However, Vidal et al. (2014)108 and Haque et al 
(2014)109 discuss that men with aggressive PCa have 
a higher risk of mortality due to the disease if they 
are overweight or obese.  
Smoking tobacco has been identified as a risk 
factor for PCa110, and our results support smoking 
tobacco being a major risk factor in individuals 
developing aggressive as well as non-aggressive 
PCa. Our results suggest that more than half of our 
patient cohort identified themselves as ever 
smokers, and this is very similar to the results 
discussed by Huncharek et al. (2010)110 and 
Braithwaite et al. (2012)111. In another study carried 
out by Pantarotto et al. (2007)112, previous and 
present tobacco smokers have been associated with 
a greater risk of PCa metastasizing. Tobacco 
smoking, has previously also been reported as a risk 
factor for PCa as a whole, compared with age and 
ethnicity matched healthy controls by our group7,10. 
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A systematic review in 2014 indicated that tobacco 
smoking is a risk factor for fatal prostate cancer but 
not a risk factor for prostate cancer incidence113. 
Adding to the published work by Islami et al. 
(2014), Sclatmann and Blanker (2015) indicated that 
the mortality risk due to tobacco use was higher in 
the pre-PSA era and not in the post-PSA era113,114. 
Tobacco use being a risk factor for both aggressive 
and non-aggressive PCa in our New Zealand cohort 
is concerning as it indicates a scenario similar to that 
of the pre-PSA era from other western countries. 
The possibility of former tobacco smokers changing 
their lifestyle after being identified as having PCa, 
or being in a high risk population, has also been 
reported by Blanchard et al. (2003). However, 
unlike the alcohol consumption changes observed in 
our study cohorts, the frequency of men ever 
exposed to tobacco smoking in both aggressive 
(54.8%) and non-aggressive (51.06%) groups has 
not declined (53.1% in 2012)107.  
Alcohol consumption, in spite of being well-
documented as a potential cause of cancer115,116, is 
yet to be proven as a risk factor for PCa117,118. Unlike 
the results of Zuccolo et al. (2013), who have shown 
a moderate risk of aggressiveness with alcohol 
consumption118, our study has found inverse 
significance related to alcohol consumption when 
comparing data obtained from groups of aggressive 
PCa vs controls as well as non-aggressive PCa vs 
controls. Additionally, previous publications from 
our group with the initial 264 PCa patients recruited 
within one year of PCa diagnosis, has recorded that 
72% of patients were alcohol consumers7. The 
current decline in alcohol consumption rate to 59% 
in patients with aggressive PCa and 56% in patients 
with non-aggressive PCa could well be due to PCa 
survivors changing their behavior and consuming 
less alcohol.  
4.4 Correction for gene x environment interaction 
and risk of prostate cancer: 
Knowledge of gene–environment interaction is 
important for risk prediction and the identification 
of certain high-risk populations to inform public 
health strategies for targeted prevention119. We 
associated the environmental factors with the 
genotypes of the men in our study to identify the risk 
alleles for specific modifiable factors such as BMI, 
smoking tobacco and alcohol consumption. Since 
these factors play an important role in the risk 
association of PCa and yet can be controlled by 
individuals, they therefore are of much importance 
to understand and limit this disease.  
4.4.1 Genotype and the outcome of non-aggressive 
prostate cancer (vs healthy controls): 
Many malignancies have been linked to specific 
environmental exposures120. Several environmental 
and occupational factors such as farming and use of 
pesticides, exposure to sunlight/ultraviolet radiation, 
as well as trace minerals which are commonly used 
in tyre and battery manufacturing have been studied 
for an association with PCa risk120. The factors, 
however, that initiate PCa, unfortunately, still 
remain to be identified as an essential prelude to 
strategies designed to reduce disease occurrence 121. 
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  SNPs identified as risk of aggressive PCa vs non-aggressive PCa (including environmental factors) 
  SNPs identified as risk of aggressive PCa vs non-aggressive PCa (after correcting for environmental factors)) 
 
SNPs identified as risk of aggressive PCa vs non-aggressive PCa (before and after correcting for environmental 
factors) 
Figure 1: Individual aggressive PCa risk association with SNPs, environmental factors as well as in combination of 
both compared to non-aggressive disease 
In our study, we have certain indicators in terms 
of the external or environmental factors such as 
tobacco smoking, alcohol consumption, or high 
BMI associated with the initiation of this disease, i.e. 
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with non-aggressive PCa. However, when the data 
was corrected for these aspects using PLINK and re-
analyzed, not one of the SNPs were identified as 
significantly associated with the disease. This may 
be because mammalian body is designed to fight 
unfavorable conditions122 and it is the external 
factors which influence the initiation of non-
aggressive PCa.  
4.4.2 Genotype and the outcome of aggressive 
prostate cancer (vs non-aggressive prostate cancer): 
We corrected for the effect of three prominent 
risk factors for the prognosis and progression of 
PCa- BMI, tobacco smoking and alcohol 
consumption as risk factors for aggressive PCa 
(compared to non-aggressive PCa) using PLINK and 
then analyzed the data to identify a pure genic risk 
for the disease and are mentioned in Table 3.1. A 
wholistic approach of these external factors was 
taken into consideration while looking into the gene-
environment interaction in our study.  
Only few SNPs were identified to have 
statistically significant risk for aggressive PCa risk 
compared to that of non-aggressive disease (before 
the use of BONF). They have been illustrated in 
Figure 1.  
SNPs rs632148, rs10086908, rs887391, and 
rs16987929 were identified to be common both with 
genotypic risk as well as interacting with 
environmental risk. Common SNPs between these 
states indicate the crucial role of gene x environment 
interactions in both initiation and the progression of 
this disease.  
4.4.3 Genotype and the outcome of aggressive 
prostate cancer (vs healthy controls): 
We continued to analyze the effect of the three 
aforementioned risk factors on the genotype in our 
population for the prognosis of PCa by statistically 
correcting it using PLINK. The same wholistic 
approach as previously mentioned, in terms of the 
external factors were taken into consideration while 
looking into the gene-environment interaction in our 
study. 
A higher number of SNPs were identified to 
have statistically significantly increased interactions 
with external factors in producing aggressive PCa 
compared to that of healthy controls (before the use 
of BONF) than the SNPs which potentially had a 
genic effect on the disease. They have been 
summarized in Figure 2.  
Of the 9 SNPs that came up significantly 
associated with aggressive PCa after correcting for 
external factors in our population,  only 2 SNPs were 
identified not to be repeats from the results already 
discussed in section 4.1.3. The higher number of 
SNPs identified in the gene x environment 
interaction category compared to in this category, 
provides statistical proof that gene x environment 
interactions play a crucial role in the progression of 
this disease. Of the SNPs that are identified in the 
genes, the expression of which may be independent 
of the environmental, or external factors (Table 3.2), 
were rs5845 and rs1799977.  
The SNP rs5845 present in the gene SEP15 
encoding for selenoprotein containing 
selenocysteine is involved in the quality control of 
protein folding123. The A allele of this SNP has a 
unique effect on PCa risk even compared to benign 
urology disease7. The SNP rs1799977 present in the 
gene MLH1, plays a major role in mismatch 
repair124. The SNP rs10896469 present near 
MYEOV, a putative oncogene, as previously 
mentioned to be frequently amplified in a number of 
tumours71,73,125.  
Interestingly, certain SNPs showing significant 
associations as risk for aggressive PCa did not show 
significant associations when interacting with 
environmental factors. In contrast, the SNPs that 
showed the strongest evidence for interactions with 
environmental factors did not show significant in 
pure SNP effect associations.  
This finding reveals that in a study like ours, it is 
very important to not only consider the SNPs 
identified by a GWAS, but also consider genotype 
(additive or dominant) by environmental (local to 
the population studied) interaction effects on 
aggressive PCa in addition to established 
associations. If this is avoided, such variants may be 
ignored. Therefore, the list of SNPs to be studied and 
eventually followed up for replication or 
confirmation changes with the genotype x 
environmental interaction effects should be 
extensive and not limited to just the ones reported in 
certain populations ignoring the local factors which 
may be pivotal for the final expression of genes. 
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We would also like to point out that, SNPs with 
statistically significant genotype x environmental 
interaction did not necessarily have a significant (or 
even suggestive) association with aggressive PCa.  
Thus, limiting interaction tests to markers with 
significant main SNP effects would likely find 
different results, and will aid in identifying a much 
better localized cause of diseases, as has also been 
mentioned by Arya et al., (2009)25. Since the 
genetics of aggressive PCa is still largely unknown, 
we cannot comment whether this approach would 
lose power or would protect against false positives 
because the underlying genetic architecture of 
aggressive PCa is largely unknown and more 
research needs to be done in this field of study, but 
we believe this is the right direction to move 
forward.
 
  SNPs identified as risk of aggressive PCa vs Healthy Controls (including environmental factors) 
  SNPs identified as risk of aggressive PCa vs Healthy Controls (after correcting for environmental factors)) 
 SNPs identified as risk of aggressive PCa vs Healthy Controls (before and after correcting for environmental factors) 
Figure 2: Individual aggressive PCa risk association with SNPs, environmental factors as well as in combination of 
both compared to controls
5. Conclusions  There is an urgent need to develop a biomarker for PCa with high sensitivity, and specificity to an 
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individual’s risk of developing the aggressive form 
of the disease126. A considerable number of patients 
with aggressive PCa are being under-treated127. The 
results obtained are suggestive of certain genes 
being associated with aggressive PCa. The data 
generated, suggest that SNP genotyping as a 
screening tool, along with other prevalent diagnostic 
tools, has the potential to help identify men heading 
towards lethal aggressive PCa at an earlier stage. 
Although epidemiological studies have shown 
an association with PCa, such that patients with 
diabetes mellitus have been suggested to be at a 
lower risk of PCa98, or an inverse association128, we 
did not find any direct and/or indirect effect of BMI 
on SNPs identified to have a risk association with 
non-aggressive PCa, but with aggressive PCa in our 
population. It has been proven that BMI has a strong 
association with diabetes mellitus and insulin 
resistance129 and with PCa130. We believe that 
obesity is linked with diabetes mellitus and PCa 
alike, and it is not diabetes mellitus which has a 
direct relation with PCa, but obesity.  
The fact that a number of SNPs in various genes 
were identified to be associated with a risk of 
prostate cancer calls for detailed work in this aspect 
for risk of PCa. We observed that the SNPs 
vulnerable to environmental conditions discussed 
here do not play a role in the initiation of the disease, 
and as the progression of PCa was mapped, we 
found an increasing role of environmental factors. It 
is also worthy of mention that the various external 
factors described here, such as increasing BMI36, 
and wide-spread tobacco smoking in New 
Zealand36, and deficiency of trace elements such as 
selenium in the New Zealand soil131 may be playing 
a much more important role in the expression and 
progression of PCa in our population than they have 
been previously credited for and need to be further 
looked into. These factors may be very crucial for 
the progression of the disease and our gene x 
environment logic is strengthened by the findings in 
our unique population.  
We identified that the SNPs rs17793693 in the 
gene PPAR-Ȗ and rs2727270 in the gene FADS2 
were risk for aggressive PCa before correction for 
environmental factors was carried out However, 
after correcting for multiple factors, these SNPs did 
not figure as a risk for aggressive PCa. We also 
identified the SNP rs4965373 in the gene SEPS1 to 
be significantly associated with risk for non-
aggressive PCa (vs healthy controls), but, again, 
when corrected for, did not come up as a risk 
association for the disease. Interestingly, though, we 
identified another SNP rs5845 in another 
selenoprotein gene- SEP15 when we corrected the 
SNP association for aggressive PCa (vs healthy 
controls) for multiple factors. This is very unique to 
the environmental conditions in New Zealand, 
where a selenoprotein SNP may trigger the start of 
the disease, but is eventually controlled due to the 
lack of selenium in the New Zealand soil, and is 
effectively checked in the eventual progress of the 
disease, unlike if it is the case when proper intake of 
selenium is not practiced. 
These curious associations and links leading to 
aggressive and non-aggressive PCa are better 
explained in the pictorial conclusion provided 
herewith (Figure 3). 
Figure 3: Pictorial conclusion illustrating the various 
associations and links leading to aggressive and non-
aggressive PCa 
Figure legends - Non-Agg: Non-aggressive PCa patients; Agg: 
Aggressive PCa patients; Con: Healthy Controls 
Supplementary Materials:  
Supplementary Table 1: Selected SNPs for present 
study.  
Supplementary Table 2: Gene x environment 
association analysis of SNPs as risk for PCa 
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